Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.

Am J Hematol 2015 Oct 10;90(10):910-4. Epub 2015 Sep 10.

Department of Health Sciences, University Of Milano-Bicocca, Monza, Italy.

Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even undetectable BCR-ABL1 by Q-RT-PCR does not equate to eradication of the disease. Digital-PCR (dPCR), able to detect 1 BCR-ABL1 positive cell out of 10(7) , has been recently developed. The ISAV study is a multicentre trial aimed at validating dPCR to predict relapses after imatinib discontinuation in CML patients with undetectable Q-RT-PCR. CML patients under imatinib therapy since more than 2 years and with undetectable PCR for at least 18 months were eligible. Patients were monitored by standard Q-RT-PCR for 36 months. Patients losing molecular remission (two consecutive positive Q-RT-PCR with at least 1 BCR-ABL1/ABL1 value above 0.1%) resumed imatinib. The study enrolled 112 patients, with a median follow-up of 21.6 months. Fifty-two of the 108 evaluable patients (48.1%), relapsed; 73.1% relapsed in the first 9 months but 14 late relapses were observed between 10 and 22 months. Among the 56 not-relapsed patients, 40 (37.0% of total) regained Q-RT-PCR positivity but never lost MMR. dPCR results showed a significant negative predictive value ratio of 1.115 [95% CI: 1.013-1.227]. An inverse relationship between patients age and risk of relapse was evident: 95% of patients <45 years relapsed versus 42% in the class ≥45 to <65 years and 33% of patients ≥65 years [P(χ(2) ) < 0.0001]. Relapse rates ranged between 100% (<45 years, dPCR+) and 36% (>45 years, dPCR-). Imatinib can be safely discontinued in the setting of continued PCR negativity; age and dPCR results can predict relapse.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24120DOI Listing
October 2015
48 Reads

Publication Analysis

Top Keywords

cml patients
12
patients
10
dpcr predict
8
isav study
8
imatinib
5
q-rt-pcr
5
months
5
q-rt-pcr bcr-abl1/abl1
4
study enrolled
4
bcr-abl1/abl1 01%
4
01% resumed
4
enrolled 112
4
resumed imatinib
4
imatinib study
4
median follow-up
4
months fifty-two
4
fifty-two 108
4
108 evaluable
4
216 months
4
follow-up 216
4

References

(Supplied by CrossRef)
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger et al.
Blood 1997
How I treat newly diagnosed chronic myeloid leukemia in 2015
Gambacorti-Passerini et al.
Am J Hematol 2015

Similar Publications